On March 8, 2022 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4, has been selected for an oral presentation at the upcoming 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 8-13, 2022 in New Orleans, LA (Press release, Bicycle Therapeutics, MAR 8, 2022, View Source [SID1234609718]). The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details

Title: BT8009-100 Phase I/II Study of Novel Bi-Cyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression
Abstract #: 7971
Presenter: Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology
Session Title: Biomarker Advances in Clinical Trials
Date/Time: Sunday, April 10, 2022 at 4:00 p.m. ET

Poster Presentation Details

Title: Development of a CD137 Receptor Occupancy Assay to Support the Phase I/II Study of BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA)
Abstract #: 5555
Presenter: Heather Cohen, Bicycle Therapeutics
Session Title: Immune Response to Therapies / Immune Monitoring and Clinical Correlates
Date/Time: Monday, April 11, 2022 at 2:30 p.m. ET

Title: Activity of the Erythropoietin-Producing Hepatocellular A2 Receptor (EphA2) Targeting Bicycle Toxin Conjugate (BTC) BCY6033 in EGFR Inhibitor Resistant Non-Small Lung Cancer (NSCLC) Patient Derived Xenografts
Abstract #: 333
Presenter: Kenneth Ngo, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
Session Title: Biological Therapeutic Agents and Novel Drugs
Date/Time: Sunday, April 10, 2022 at 2:30 p.m. ET

Title: Modeling the cDC1 Ex Vivo and In Vitro: Development and Characterization of a Conventional Dendritic Cell Culture System to Support Drug Discovery
Abstract #: 4230
Presenter: Laura Goodfield, Bicycle Therapeutics
Session Title: Immunomodulatory Agents and Interventions 3
Date/Time: Wednesday, April 13, 2022 at 10:00 a.m. ET

Title: Generation of a Bicycle NK-TICA, a Novel NK Cell Engaging Molecule Designed to Induce Targeted Tumor Cytotoxicity
Abstract #: 4233
Presenter: Fay Dufort, Bicycle Therapeutics
Session Title: Immunomodulatory Agents and Interventions
Date/Time: Wednesday, April 13, 2022 at 10:00 a.m. ET

The posters and a copy of the presentation will be available on the Publications section of bicycletherapeutics.com following presentation.

Conference Call Details

Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m. ET to review the data being presented. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.